NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 165 filers reported holding NEVRO CORP in Q2 2019. The put-call ratio across all filers is 5.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $151,242 | +6.8% | 7,869 | +41.3% | 0.00% | – |
Q2 2023 | $141,564 | -93.4% | 5,569 | -87.9% | 0.00% | -100.0% |
Q3 2022 | $2,151,000 | +2929.6% | 46,159 | +4586.2% | 0.00% | – |
Q1 2022 | $71,000 | +222.7% | 985 | +263.5% | 0.00% | – |
Q4 2021 | $22,000 | -26.7% | 271 | +25.5% | 0.00% | – |
Q3 2020 | $30,000 | -94.9% | 216 | -96.9% | 0.00% | -100.0% |
Q3 2019 | $591,000 | -20.5% | 6,871 | -40.1% | 0.01% | -28.6% |
Q2 2019 | $743,000 | +698.9% | 11,463 | +674.0% | 0.01% | +600.0% |
Q1 2019 | $93,000 | -35.9% | 1,481 | -18.2% | 0.00% | 0.0% |
Q2 2018 | $145,000 | -37.8% | 1,810 | -29.5% | 0.00% | -50.0% |
Q3 2017 | $233,000 | +913.0% | 2,569 | +742.3% | 0.00% | – |
Q2 2017 | $23,000 | -77.0% | 305 | -71.4% | 0.00% | -100.0% |
Q1 2017 | $100,000 | +29.9% | 1,068 | +1.2% | 0.00% | 0.0% |
Q4 2016 | $77,000 | -78.4% | 1,055 | -83.4% | 0.00% | -80.0% |
Q1 2016 | $357,000 | +243.3% | 6,341 | +184.2% | 0.01% | +400.0% |
Q3 2015 | $104,000 | – | 2,231 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |